Friday , July 20 2018
Home / Letter From The Editor / April 14, 2018

April 14, 2018

Apr 14, 2018
 

A couple of days ago we sent out our latest therapy update on SGLT-2 Inhibitors. This class of drugs shows multiple ways to decrease A1c values with a small risk of hypoglycemia. This means that individual glucose levels often are not of concern. This is not true with our insulin-using patients and many of them don’t maximize therapy in order to avoid low glucose readings.

This week, our good friend from Diabetic Investor, David Kliff, gives us an update on what is happening with CGMS, Insulin Pumps, Smart Pens and Software, and what the future holds for managing tighter control.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief